At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,107 enrolled
Drug / intervention
Compound Sodium Alginate Double Action Chewable Tablets +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multi-centre, Randomised, Double-blind, Two Arm, Parallel Group, Placebo-controlled Study to Assess the Effect of Compound Sodium Alginate Double Action Chewable Tablets in Patients With Gastro-esophageal Reflux Disease
In Brief
A Phase 3 clinical trial evaluating Compound Sodium Alginate Double Action Chewable Tablets and Matching placebo tablets for Gastroesophageal Reflux Disease and Dyspepsia. Completed, enrolled 1,107 participants across 2 sites.
Detailed Summary
This study is being conducted to provide evidence that Compound Sodium Alginate Double Action Chewable Tablets are effective in managing the symptoms of heartburn, acid regurgitation and dyspepsia in patients with Gastroesophageal Reflux Disease (GERD).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGastroesophageal Reflux Disease, Dyspepsia
CountriesChina
Collaborators--
Timeline
Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJun 2013
Enrollment StartJun 2013
Primary CompletionMay 2014
TodayJul 2026
First PostedJun 5, 2013
Enrollment StartJun 5, 2013
Primary CompletionMay 1, 2014
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 13.1 years ago
Interventions
Compound Sodium Alginate Double Action Chewable Tabletsdrug
2 tablets four times daily
Matching placebo tabletsdrug
2 tablets four times daily